GALT

Galectin Therapeutics Inc.

3.14

USD

+0.16

+5.19%

Nov 06, 15:59 UTC -5

Closed

After-Market

3.04

-0.10

-3.03%

Galectin Therapeutics Inc. (GALT) Earnings

GALT Earnings Reports

Positive Surprise Ratio

GALT beat 30 of 43 last estimates.

70%

Next Report

In 3 Days

Date of Next Report

Nov 12, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.05

Implied change from Q2 26 (Revenue/ EPS)

-64.29%

Implied change from Q3 25 (Revenue/ EPS)

-61.54%

Galectin Therapeutics Inc. earnings per share and revenue

On Aug 14, 2026, GALT reported earnings of -0.14 USD per share (EPS) for Q2 26, missing the estimate of -0.09 USD, resulting in a -52.51% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.55% price change (close before vs. close after earnings).

Looking ahead to Q3 26, -- analysts forecast an EPS of -0.05 USD, with revenue projected to reach -- USD, implying an decrease of -64.29% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Aclaris Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.12

Surprise

+28.49%

Protara Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.35

Surprise

+6.17%

Minerva Neurosciences, Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.12

Actual

$1.94

Surprise

+1,629.97%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Dyne Therapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.92

Actual

-$1.06

Surprise

-15.57%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

Aldeyra Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.06

Surprise

+37.43%

Lipocine Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.36

Actual

-$0.08

Surprise

+77.91%

FAQ

What were Galectin Therapeutics Inc.'s earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Galectin Therapeutics Inc. reported EPS of -$0.14, missing estimates by -52.51%, and revenue of $0.00, 0% as expectations.

How did the market react to Galectin Therapeutics Inc.'s Q2 2026 earnings?

The stock price moved down -2.55%, changed from $3.53 before the earnings release to $3.44 the day after.

When is Galectin Therapeutics Inc. expected to report next?

The next earning report is scheduled for Nov 12, 2026.

What are the forecasts for Galectin Therapeutics Inc.'s next earnings report?

Based on -- analysts, Galectin Therapeutics Inc. is expected to report EPS of -$0.05 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.